Nicholas Lydon, Director at Blueprint Medicines Corp (BPMC), sold 25,000 shares at $85.75 ($2.1M) on 2019-06-12, disclosed to the SEC on 2019-06-14.
Open-market sale of $2.1M BPMC by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $81.96 | 300 | $25K | 1.2% |
| 2 | $82.45 | 2,000 | $165K | 7.8% |
| 3 | $83.83 | 5,200 | $436K | 20.6% |
| 4 | $84.66 | 6,300 | $533K | 25.2% |
| 5 | $85.75 | 11,200 | $960K | 45.3% |
| Total | $84.77 avg | 25,000 |
| $2.1M |
| 100% |
| Filing → |
| BPMC | SELL | 2020-07-08 | $4.1M | — | Filing → |
| BPMC | SELL | 2020-07-06 | $661K | — | Filing → |
| BPMC | SELL | 2020-06-25 | $32K | — | Filing → |